References of "Piront, Patricia"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTraitement des carcinomes hépatocellulaires à un stade avancé
Van Daele, Daniel ULg; Belaiche, Jacques ULg; Delwaide, Jean ULg et al

in Revue Médicale de Liège (2009), 64(3), 140-147

Hepatocellular carcinoma is the main primitive tumor of the liver. It occurs in the setting of liver cirrhosis in more than 90% of the cases in developping countries. The prognosis depends on the size ... [more ▼]

Hepatocellular carcinoma is the main primitive tumor of the liver. It occurs in the setting of liver cirrhosis in more than 90% of the cases in developping countries. The prognosis depends on the size, number and extension of the tumor as well as on the severity of the underlying liver disease. The Barcelona Clinic Classification takes into account these different parameters and helps the clinician in the therapeutic decision. Some patients (around 25%) are amenable to therapy with a curative intent (liver transplantation, resection, destruction by radiofrequency). In patients with hepatocellular carcinoma at an intermediate stage, lipiodolized chemoembolization gives a survival advantage in comparison with placebo. No conventional regimen of chemotherapy has a proven survival benefit. In patients with a hepatocellular carcinoma at an advanced stage, sorafenib, an oral multi-targeted kinase inhibitor, is the first coumpound to demonstrate a significant effect on survival free of disease progression in a selected group of patients. Its toxicity profile is particularly favourable. Combination of surgical and medical therapies should be properly evaluated in clinical trials in the near future. [less ▲]

Detailed reference viewed: 220 (9 ULg)
Full Text
Peer Reviewed
See detailSurgical management of hepatic metastases of colorectal origin.
Gilson, Nathalie; Honore, Charles ULg; Detry, Olivier ULg et al

in Acta Gastro-Enterologica Belgica (2009), 72(3), 321-6

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or ... [more ▼]

Colorectal cancer is the most frequent digestive cancer. Prognosis is greatly depending on the TNM stage at the time of diagnosis. Fifty percent of all patients shall develop, synchronously or metachronously, liver metastases. Different means such as chemotherapy, targeted therapies, radiofrequency ablation, portal vein embolization and two-stage hepatectomy may be used to make these metastases eventually resectable and to increase overall survival. This is a short review of these different methods used to increase resectability but also on the integration of these parameters in a larger approach of colorectal liver metastasis surgery especially insisting on multidisciplinary discussion. [less ▲]

Detailed reference viewed: 101 (6 ULg)
Full Text
Peer Reviewed
See detailQuand doit-on réséquer les métastases hépatiques d'un cancer colorectal?
Honoré, Charles ULg; Detry, Olivier ULg; Deroover, Arnaud ULg et al

in Revue Médicale de Liège (2008), 63(10), 595-599

6000 new cases of colorectal cancer are diagnosed each year in Belgium. 50% of these patients shall develop liver metastasis. Resection remains the only chance of long term survival and must be considered ... [more ▼]

6000 new cases of colorectal cancer are diagnosed each year in Belgium. 50% of these patients shall develop liver metastasis. Resection remains the only chance of long term survival and must be considered as an endpoint from the beginning of the treatment. It is the result of a multidisciplinary discussion and a global approach of the disease. It is rarely directly feasible, but there are many techniques which may make it achievable in the end. Today, resection criteria are exclusively technical and neitherbad prognosis factors, nor the presence of extra-hepatic metastases should exclude liver resection. This resecability must be assessed by a confirmed hepatobiliary surgeon and must be proposed to all patients whatever their age as long as their global status is good. [less ▲]

Detailed reference viewed: 130 (9 ULg)
Full Text
Peer Reviewed
See detailLe depistage du cancer colorectal
Piront, Patricia ULg; Louis, Edouard ULg; Belaiche, Jacques ULg et al

in Revue Médicale de Liège (2007), 62(1), 15-20

Colorectal cancer is the second leading cause of death in Northern countries and need a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼]

Colorectal cancer is the second leading cause of death in Northern countries and need a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲]

Detailed reference viewed: 111 (2 ULg)
Full Text
Peer Reviewed
See detailScreening for colorectal cancer in 2006
Piront, Patricia ULg; Louis, Edouard ULg; Belaiche, Jacques ULg et al

in Acta Endoscopica (2007), 37(3), 305-313

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and ... [more ▼]

Colorectal cancer is the second leading cause of death in Northern countries and needs a national screening program to reduce mortality and improve quality of life. Screening has to be cost-effective and acceptable for patients. Many screening tools, invasive or not, are existing and often debated: FOBT, sigmoidoscopy and complete colonoscopy. New tools are in development and have to be evaluated in current practice: virtual colonoscopy, new endoscopic technologies, DNA on faeces or proteomics with markers in serum. [less ▲]

Detailed reference viewed: 20 (2 ULg)
Full Text
See detailEvolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003
Vijverman, A.; Piront, Patricia ULg; Belaiche, Jacques ULg et al

in Acta Gastro-Enterologica Belgica (2006), 69(1, Jan-Mar), 1-4

Introduction : Anemia has been considered as an overlooked complication of inflammatory bowel disease. Studies dating back to the 80ties and the 90ties have shown 30% of anemia among inflammatory bowel ... [more ▼]

Introduction : Anemia has been considered as an overlooked complication of inflammatory bowel disease. Studies dating back to the 80ties and the 90ties have shown 30% of anemia among inflammatory bowel disease (IBD) patients. More recently, the broader use of immunosuppressive drug and infliximab allowing better mucosal healing as well as a more aggressive treatment of anemia, including the use of safer form of IV iron, may have influenced the prevalence of anemia among IBD patients. Our aim was to asses the prevalence and characteristics of anemia among two cohorts of IBD patients at 10 years interval and to look for associated clinical or demographic factors. Methods: using the IBD patients register of one senior gastroenterologist, we identified IBD patients he had consecutively seen and who had blood test at the outpatient clinic during the years 1993 and 2003. Demographic and clinical characteristics, treatment for Crohn's disease, blood test results and treatment of anemia were recorded and compared between these two cohorts. Anemia was defined as an hemoglobin level lower than the normal value of the laboratory of our hospital. Results : 80 and 90 patients were identified in 1993 and 2003, respectively. There was no significant difference between the two cohorts, according to age, gender, disease type, duration or location. There were 27/80 (33.8%) and 15/90 (16.7%) anemic patients in 1993 and 2003, respectively (P = 0.013). The prevalence of severe anemia (hemoglobin level < 10.5 g/100 ml) was similar in the two cohorts (6.3% and 5.6%). Characteristics of the anemia were similar in the two cohorts with a majority of iron deficiency anemia and inflammatory anemia. Ferritin and CRP levels were not significantly different in the two cohorts. The only significant difference was a more frequent use of immunosuppressive treatment and infliximab in 2003 than in 1993 (33.3% vs. 13.8%; P = 0.0038, RR :0.41, 0.22-0.77) Conclusions : Prevalence of mild to moderate anemia has significantly decreased in our population over the last 10 years. The only difference detected between the two cohorts was the increased use of immunosuppressive drug (mainly azathioprine). [less ▲]

Detailed reference viewed: 38 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention primaire et secondaire du cancer colorectal
Polus, Marc ULg; Piront, Patricia ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2003), 58(4), 247-53

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed ... [more ▼]

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed, particularly by aspirin and non steroidal anti-inflammatory drugs. Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality. [less ▲]

Detailed reference viewed: 120 (2 ULg)
Full Text
See detailRevue de l'épidémiologie de la maladie de Crohn en Europe
Piront, Patricia ULg; Belaiche, Jacques ULg; Louis, Edouard ULg

in Acta Endoscopica (2003), 33

Detailed reference viewed: 46 (2 ULg)
Full Text
Peer Reviewed
See detailDécompensation cardiaque, fonction rénale et anti-inflammatoires non stéroïdiens
Krzesinski, Jean-Marie ULg; Piront, Patricia ULg

in Revue Médicale de Liège (2002), 57(9), 582-586

Thanks to a case report of heart failure in an old people with a cardiovascular history treated by the new coxib-inhibitors, we would like to remember and insist to the risk of renal and cardiac ... [more ▼]

Thanks to a case report of heart failure in an old people with a cardiovascular history treated by the new coxib-inhibitors, we would like to remember and insist to the risk of renal and cardiac complications which appear to be the same as those with the non specific antiinflammatory drugs. Old age, diuretic or converting enzyme inhibitor treatment, heart failure, liver insufficiency, nephrotic syndrome are risk factors for acute renal failure and cardiac failure during such treatment. [less ▲]

Detailed reference viewed: 723 (6 ULg)
Full Text
Peer Reviewed
See detailEpidemiology of inflammatory bowel diseases in the elderly in the province of Liege - A three-year prospective study
Piront, Patricia ULg; Louis, Edouard ULg; Latour, Pascale ULg et al

in Gastroentérologie Clinique et Biologique (2002), 26(2), 157-161

Detailed reference viewed: 24 (0 ULg)